Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAKâ•’906), a Novel Selective D2/D3 Receptor Antagonist: A Phase 1 Randomized, Placeboâ•’Controlled Singleâ•’ and Multipleâ•’Dose Escalation Study in Healthy Participants